We recently published a list of Top 11 Small Cap Stocks to Buy with Biggest Upside Potential. In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other top small cap stocks to buy with biggest upside potential.
On April 24, Jill Carey Hall, BofA Securities head of U.S. small/mid-cap strategy, appeared on ‘Closing Bell’ to talk about the impact of tariffs on small caps. She also discussed the outlook for the category, saying that the earnings backdrop is essential. When we look back a year ago, investors were excited about small caps, as the earnings were recovering and the market was coming out of the 2023 earnings recession. Everyone expected that these stocks would see double-digit earnings growth by mid-last year, outpacing large caps. That got pushed out for over a year, and now the sector has sold off a lot.
While we have gotten some potential good news on tariffs, there is still a lot of uncertainty, and we are in a backdrop where earnings revisions have still been negative. She opined that she would feel more comfortable if we were in a backdrop where there was confidence in earnings recovery because last earnings season, the commentary was a lot more negative from small-cap companies than large-cap companies. So far, this earnings season is still early for small caps, but guidance in both large and small has been weak.
Hall said that the sector would see a much better picture if earnings revisions turned around with higher confidence, and not only the tariffs were better than expected but also the economic backdrop was better. However, we are also in a place where economists think the Fed will stay on hold this year, and the Russell has been very sensitive to Fed expectations. Her outlook for small caps thus points towards a more credit-sensitive environment highly tethered to Fed expectations, with no anticipation of a rate cut this year. She also highlighted that looking at corporate commentary as small-cap reporting kicks off is important.
Not all small caps are created equal, even when some people consider them to be so. Hall opined that this is definitely a year where you want to be selective in small caps, focusing on stocks with strong margins amid tariff uncertainty. She favored high-quality domestic stocks, steering clear of tariff and refinancing risks and focusing on stocks with positive revisions in this broad backdrop of negative revisions. There are groups of stocks that are more sensitive to tariffs, just as there are groups that are more global and domestic. Similarly, some groups are more levered with higher refinancing risks within small caps if the rate stays higher and credit spreads stay elevated.
Therefore, she reasoned that she would stick with higher-quality stocks that are more profitable and have strong operating margins. Stocks with these characteristics have been some of the top performers within the industry amid tariff risks. From a sector perspective, if investors want to be more defensive, utilities screen well across the work, both in small and large caps.
There will thus be opportunities in the segment, according to Hall, but one needs to be selective. She also expressed positive sentiments for mid-caps, which have been one of the best performers in the sector this year. They have seen much better revision trends, cleaner balance sheets, and fewer risks from potential earnings hits from tariffs than small caps because the latter have thinner margins and could see a greater hit.
We sifted through stock screeners, financial media reports, and ETFs to compile a list of 30 small cap stocks and chose the top 11 with the biggest analyst upside potential as of May 2, 2025. We also included the number of hedge fund holders as of Q4 2024, which we sourced from Insider Monkey’s database. The list is presented in ascending order of stocks’ upside potential.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 363.5% since May 2014, beating its benchmark by 208 percentage points (see more details here).
A scientist in a lab coat analyzing a Petri dish surrounded by scientific equipment in a research lab.
Market Cap: $1.93 billion
Analyst Upside: 198.78%
Number of Hedge Fund Holders: 34
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) is a biopharmaceutical company that develops medicines to treat intractable diseases by silencing the genes causing them. Its preclinical stage drug candidates are ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC.
On March 10, analyst Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) and set a $80.00 price target. The analyst said the company holds a promising future outlook because of its complement disease program. Its Phase 1/2 trial of ARO-C3 delivered positive results for treating complement-mediated renal diseases. It exhibited a notable decrease in complement activity and proteinuria, reflecting its potential as a potentially blockbuster therapy. The data showed that ARO-C3 did not include severe adverse events and was well-tolerated, with its durability highlighting a competitive advantage with less frequent dosing than other therapies.
The analyst also said that Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) boasts a robust pipeline with other promising candidates as well, including ARO-CFB, which addresses non-renal complement-mediated diseases. The company has a strategic approach to the advancement of its candidates, and despite market competition and risks of clinical development, ARO-C3 and other products in its pipeline hold the potential to address unmet medical needs, supporting the buy rating.
Overall, ARWR ranks 6th on our list of top small cap stocks to buy with biggest upside potential. While we acknowledge the potential for ARWR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than ARWR but trades at less than 5 times its earnings, check out our report about thischeapest AI stock.
Add Comment